Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
October 02, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
September 21, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
September 07, 2023 07:03 ET
|
Axsome Therapeutics, Inc.
Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW...
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
September 05, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Total 2Q 2023 product revenue of $46.7 million Auvelity® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi® 2Q 2023 net product revenue...
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
July 12, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
July 07, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
June 30, 2023 16:02 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the...
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
June 28, 2023 09:28 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the...
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
June 27, 2023 20:24 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing novel therapies for the management of central...